Innoviva, Inc.
INVA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.6B
$21.33
▼ -0.09%
P/E
4.85
Mkt Cap
$1.6B
52-Wk Range
$16.52–$25.15
52-Week Range
$16.52 - $25.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 4.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ELLIPTA dry powder inhaler technology enabling once-daily dosing
- Strategic partnership with GSK providing global commercialization and distribution capabilities
- Established market presence in COPD and asthma treatment with proven efficacy and patient adoption
- Patent-protected combination therapies with multiple drug classes addressing unmet patient needs
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Expanding international markets and emerging market penetration for respiratory products
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-4.5% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INVA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $1.14 vs $0.44 consensus (+161.5% surprise). Revenue of $119.6M vs $111.0M expected (+7.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+161.5%
Revenue trend · last 8Q
—
+7%
+14%
-3%
+20%
+29%
+11%
+19%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$89.5M
$91.8M
$88.6M
$100.3M
$107.8M
$118.0M
$98.0M
$119.6M
Margins · last 8Q
Gross
75.8%
Operating
42.5%
Profit
-69.8%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 21, 2026
vs Industry
How INVA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related